Team:Valencia Biocampus/Project
The St2OOL project
Overview
Synthetic Biology implies an engineering perspective on biotechnology. Similarly to man-made objects, cells are expected to be decoupled, modified and even built from scratch. However, there is a general assent on the current difficulties for fully -and predictably- engineering living organisms, which are always subjected to strong evolutionary constraints. The St2OOL project aims at deeply studying four of the key engineering pillars of Synthetic Biology. St2OOL stands for Standardization, Stability, Orthogonality and Open Licence.
The first approach, an analytical one, will consist of a vast range of experimental studies to find out how standard, stable, orthogonal and patentable several selected Biobrick are. The second approach, a synthetic one, will include functional metagenomics: several environmental libraries will be set and screened in E. coli in order to select new biological parts -promoters-, not because of their strength but because of their particularly standard, stable or orthogonal behavior. Taken together, the results of our project are expected to contribute in answering this key question: Is life fully engineerable?
Stability
Our subteam aims to test the stability of ten different Biobricks transformed in two different strains of Escherichia coli, XL1 Blue and DH5α. Stability is determined by subjecting the transformed cells to different types of stress and comparing the output with non-transformed ones grown in the same conditions, as well as with cells transformed with an empty plasmid (without Biobrick).
Orthogonality
Do biobricks behave independently when cotransformed in a cell? In other words, can we consider them to be orthogonal? Orthogonality is a mathematical concept that refers to the independence of behavior. Translating this concept into the biological realm, two constructions can be considered orthogonal when they only interact at specific and predictable interphases and do not disturb each other. This is a desirable feature of Biobricks if one wants to build synthetic circuits with predictable and robust behaviors.
To study this pillar of synthetic biology we are analyzing different combinations of Biobricks in cotransformed cells. That way, we can study the expression of pairs of Biobricks and compare them with simple transformations, and therefore determine whether the presence of two constructions in the same cell affects their behavior. In order to do so, we will measure the output of each Biobrick (i.e. fluorescense) in both the cotransformants and the controls.
We are going to study three combinations, taking in to account that each pair of biobricks is controlled by the same promoter and only differs in the protein expressed and the antibiotic resistance:
- Constitutive promoter I (strong) – GFP & Constitutive promoter I (strong) – RFP
- Constitutive promoter II (less strong) – GFP & Constitutive promoter I (strong) – RFP
- Ptrc – lacZ & Ptrc – luciferase
Besides individually transformed cells, we will use a control consisting of cotransformed cells with a Biobrick-bearing plasmid and an empty one.
We are currently working on all this. But we have another, very ambitious experiment. We plan to determine the effect of the production of a single heterologous protein on the proteomic architecture of the host cell. For this endeavor, we just submitted our samples for a proteomic quantification.
Open License
We did not want the Human Practices section to be a cosmetic addendum to our iGEM project. In The St2OOL, we have performed a critical but constructive analysis of four of the pillars of the competition. Three of them are technical, engineering assumptions (stability, standardization, orthogonality). The fourth leg of our St2OOL is for us at least as important as the other three, and deals with the answer to this difficult question: who owns synthetic bio-constructions?
iGEM is linked to the Registry of Standard Biological Parts, a non-profit organization (as iGEM Foundation itself) archiving and distributing thousands of BioBrick parts for free (http://parts.igem.org/Main_Page). No patents, no licenses, no royalties. Just Open Access (either totally free access or under certain conditions such as a creative commons subscription). As stated in their Website, it’s “an open community that runs and grows on the Get & Give (& Share) philosophy. Users get parts, samples, data, and tools from the Registry to work on their synthetic biology projects. They will give back to the Registry the new parts they have made, as well as data and experience on new and existing parts”. But of course, the world of Biotechnology/SynBio is far more than iGEM and a range of Intellectual Property protection formulas do exist. Is iGEM an island of Free Access in an ocean of patentable SynBio achievements? How can one deal with the variety of IP forms?
The Seat of the St²OOL
By checking how standard, stable, orthogonal or patentable Biobricks are we have performed an analysis of four engineering pillars. But we wanted to combine these pillars, these four legs of our St2OOL, with a truly synthetic and constructive approach.
In The Seat of the St2OOL we are developing a functional metagenomic strategy in which we aim at isolating promoter sequences from natural
environments. We will then characterize these sequences in order to select those with the highest stability, standard and orthogonal behaviors. We are
working with soil and compost samples, from which we will isolate total metagenomic DNA, which will then be digested, ligated into an expression vector and
used to built a library in E. coli. Transformants –clones with a promoter-like natural sequence- will be subjected to a range of stresses and
subtransformation steps to find out their stability and standard/orthogonal behavior. To the best of our knowledge, this is the first Synthetic Biology
functional metagenomic approach aiming at selecting biological parts not because of their “strength” but because of their compatibility with other parts
and suitability for engineering purposes.
Finally, one technical –yet important- detail: we are not using neither commercial kits nor manual protocols for isolating metagenomic DNA. We are building our own robot…